Initial laboratory and molecular parameters and CD11b expression
. | No. of patients . | CD11b, MESF units, mean ± SE . | P . |
---|---|---|---|
Sex | |||
Male | 88 | 2390 ± 910 | .24 |
Female | 71 | 1170 ± 250 | |
Age | |||
1-9 y | 123 | 1930 ± 650 | .76 |
10-18 y | 36 | 1540 ± 480 | |
WBC count at diagnosis | |||
Less than 50.0 ×109/L (50 000/μL) | 132 | 2010 ± 620 | .50 |
More than 50.0 ×109/L (50 000/μL) | 24 | 1020 ± 370 | |
Immunophenotype | |||
Pro | 1 | 1752 | |
Common | 137 | 2000 ± 600 | .49* |
Pre | 16 | 770 ± 340 | |
Other† | 5 | ||
BCR/ABL | |||
Positive | 7 | 3420 ± 1100 | .52 |
Negative | 152 | 1780 ± 540 | |
MLL/AF4 | |||
Positive | 1 | 1960 | |
Negative | 138 | 2010 ± 590 | |
TEL/AML1 | |||
Positive | 43 | 260 ± 37 | .002 |
Negative | 113 | 2500 ± 720 | |
DNA index‡ | |||
Less than 1.16 | 118 | 1700 ± 680 | .50 |
Greater than 1.16 | 33 | 2600 ± 490 |
. | No. of patients . | CD11b, MESF units, mean ± SE . | P . |
---|---|---|---|
Sex | |||
Male | 88 | 2390 ± 910 | .24 |
Female | 71 | 1170 ± 250 | |
Age | |||
1-9 y | 123 | 1930 ± 650 | .76 |
10-18 y | 36 | 1540 ± 480 | |
WBC count at diagnosis | |||
Less than 50.0 ×109/L (50 000/μL) | 132 | 2010 ± 620 | .50 |
More than 50.0 ×109/L (50 000/μL) | 24 | 1020 ± 370 | |
Immunophenotype | |||
Pro | 1 | 1752 | |
Common | 137 | 2000 ± 600 | .49* |
Pre | 16 | 770 ± 340 | |
Other† | 5 | ||
BCR/ABL | |||
Positive | 7 | 3420 ± 1100 | .52 |
Negative | 152 | 1780 ± 540 | |
MLL/AF4 | |||
Positive | 1 | 1960 | |
Negative | 138 | 2010 ± 590 | |
TEL/AML1 | |||
Positive | 43 | 260 ± 37 | .002 |
Negative | 113 | 2500 ± 720 | |
DNA index‡ | |||
Less than 1.16 | 118 | 1700 ± 680 | .50 |
Greater than 1.16 | 33 | 2600 ± 490 |